Accordingly, we found that HCC patients with low expression of TGF-β1 had shorter OS (38.1 versus 60.5 months, p = 0.0006, Fig. 2C) and TTR (26.5 versus 41.4 moths, p = 0.0009, Fig. 2D). This evidence concerns the gene TGFB1 and hepatocellular carcinoma.